IBDEI0TA ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14448,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,14448,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,14448,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,14449,0)
 ;;=250.80^^89^893^10
 ;;^UTILITY(U,$J,358.3,14449,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14449,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,14449,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,14449,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,14450,0)
 ;;=250.00^^89^893^5
 ;;^UTILITY(U,$J,358.3,14450,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14450,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,14450,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,14450,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,14451,0)
 ;;=250.40^^89^893^6
 ;;^UTILITY(U,$J,358.3,14451,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14451,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,14451,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,14451,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,14452,0)
 ;;=250.50^^89^893^9
 ;;^UTILITY(U,$J,358.3,14452,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14452,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,14452,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,14452,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,14453,0)
 ;;=250.60^^89^893^7
 ;;^UTILITY(U,$J,358.3,14453,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14453,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,14453,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,14453,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,14454,0)
 ;;=250.70^^89^893^8
 ;;^UTILITY(U,$J,358.3,14454,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14454,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,14454,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,14454,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,14455,0)
 ;;=250.01^^89^893^4
 ;;^UTILITY(U,$J,358.3,14455,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14455,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,14455,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,14455,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,14456,0)
 ;;=272.0^^89^893^22
 ;;^UTILITY(U,$J,358.3,14456,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14456,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,14456,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,14456,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,14457,0)
 ;;=272.1^^89^893^28
 ;;^UTILITY(U,$J,358.3,14457,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14457,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,14457,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,14457,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,14458,0)
 ;;=272.2^^89^893^24
 ;;^UTILITY(U,$J,358.3,14458,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14458,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,14458,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,14458,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,14459,0)
 ;;=275.42^^89^893^21
 ;;^UTILITY(U,$J,358.3,14459,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14459,1,4,0)
 ;;=4^275.42
 ;;^UTILITY(U,$J,358.3,14459,1,5,0)
 ;;=5^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,14459,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,14460,0)
 ;;=275.41^^89^893^29
 ;;^UTILITY(U,$J,358.3,14460,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14460,1,4,0)
 ;;=4^275.41
 ;;^UTILITY(U,$J,358.3,14460,1,5,0)
 ;;=5^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,14460,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,14461,0)
 ;;=276.7^^89^893^23
 ;;^UTILITY(U,$J,358.3,14461,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14461,1,4,0)
 ;;=4^276.7
